From WikiProjectMed
Jump to navigation Jump to search
Trade namesXospata
  • 6-Ethyl-3-[3-methoxy-4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]anilino]-5-(oxan-4-ylamino)pyrazine-2-carboxamide
Clinical data
Drug classTyrosine kinase inhibitor[1]
Main usesAcute myeloid leukemia (AML)[1]
Side effectsLiver problems, tiredness, diarrhea, nausea, cough, swelling, shortness of breath, low blood pressure, pain[1]
  • AU: D[2]
  • US: N (Not classified yet)[3]
Routes of
By mouth
Typical dose120 mg OD[4]
External links
US NLMGilteritinib
License data
Legal status
  • AU: S4 (Prescription only) [2]
  • UK: POM (Prescription only) [5]
  • US: ℞-only [6]
  • EU: Rx-only [7]
  • In general: ℞ (Prescription only)
Chemical and physical data
Molar mass552.724 g·mol−1
3D model (JSmol)
  • CCc1nc(C(=O)N)c(Nc2ccc(N3CCC(CC3)N4CCN(C)CC4)c(OC)c2)nc1NC5CCOCC5
  • InChI=1S/C29H44N8O3/c1-4-23-28(31-20-9-17-40-18-10-20)34-29(26(33-23)27(30)38)32-21-5-6-24(25(19-21)39-3)37-11-7-22(8-12-37)36-15-13-35(2)14-16-36/h5-6,19-20,22H,4,7-18H2,1-3H3,(H2,30,38)(H2,31,32,34)

Gilteritinib, sold under the brand name Xospata, is a medication used to treat acute myeloid leukemia (AML).[1] Specifically it is used for cases that have failed other treatments and have a specific mutation in FLT3.[4] It is taken by mouth.[4] It may require six months for benefits to occur.[8]

Common side effects include liver problems, tiredness, diarrhea, nausea, cough, swelling, shortness of breath, low blood pressure, and pain.[1] Other side effects may include differentiation syndrome, arrhythmias, anaphylaxis, and posterior reversible encephalopathy syndrome (PRES).[1][4] Use in pregnancy may harm the baby.[4] It is a tyrosine kinase inhibitor that blocks FLT3.[1]

Gilteritinib was approved for medical use in the United States in 2018, Europe in 2019, and Australia in 2020.[6][1][9] In the United Kingdom 4 weeks of treatment costs the NHS about £14,200 as of 2021.[8] In the United States this amount costs about 23,700 USD.[10]

Medical uses


It is generally taken at a dose of 120 mg per day.[4] Doses of up to 200 mg per day may be used if no response to smaller doses.[8]


In April 2018, Astellas filed a new drug application with the Food and Drug Administration for gilteritinib for the treatment of adult patients with FLT3 mutation–positive relapsed or refractory acute myeloid leukemia (AML).[11]

Gilteritinib was granted orphan drug status in the United States, Europe, and Japan.[12]


Gilteritinib has been repurposed as a potential antiviral drug as a possible application in the treatment of COVID-19.[13]


  1. 1.0 1.1 1.2 1.3 1.4 1.5 1.6 1.7 "Xospata". Retrieved 3 December 2021.
  2. 2.0 2.1 "Xospata Australian prescription medicine decision summary". Therapeutic Goods Administration (TGA). 11 April 2020. Retrieved 16 August 2020.
  3. "Gilteritinib (Xospata) Use During Pregnancy". 20 August 2019. Retrieved 16 August 2020.
  4. 4.0 4.1 4.2 4.3 4.4 4.5 "Gilteritinib Monograph for Professionals". Retrieved 3 December 2021.
  5. "Xospata 40 mg film-coated tablets - Summary of Product Characteristics (SmPC)". (emc). 13 November 2019. Retrieved 16 August 2020.
  6. 6.0 6.1 "Xospata- gilteritinib tablet". DailyMed. 31 May 2019. Retrieved 16 August 2020.
  7. "Xospata EPAR". European Medicines Agency (EMA). 16 September 2019. Retrieved 16 August 2020.
  8. 8.0 8.1 8.2 BNF 81: March-September 2021. BMJ Group and the Pharmaceutical Press. 2021. p. 1027. ISBN 978-0857114105.
  9. "AusPAR: Gilteritinib (as fumarate)". Therapeutic Goods Administration (TGA). 11 September 2020. Retrieved 23 September 2020.
  10. "Xospata Prices, Coupons & Patient Assistance Programs". Retrieved 3 December 2021.
  11. "FDA Approval Sought for Gilteritinib in FLT3+ AML". April 24, 2018. Retrieved September 29, 2018.
  12. "U.S. FDA Grants Priority Review to Astellas' New Drug Application for Gilteritinib for the Treatment of Adult Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML)". Retrieved 2018-12-03.
  13. Bouhaddou M, Memon D, Meyer B, White KM, Rezelj VV, et al. (2020-08-06). "The Global Phosphorylation Landscape of SARS-CoV-2 Infection". Cell. 182 (3): 685–712.e19. doi:10.1016/j.cell.2020.06.034. PMC 7321036. PMID 32645325.

External links

External sites: